Memorial Hospital Research Laboratories

The Michelle Bradbury Lab

Share
Print
Back to Top

Research

Michelle S. Bradbury, MD, PhD
Director of Intraoperative Imaging, Radiology

I am a clinician-scientist with experience in the application of a wide range of molecular imaging tools in both preclinical and clinical settings. At Memorial Sloan Kettering, I direct a laboratory that focuses on the development, characterization, and evaluation of translational silica nanomaterials for cancer applications. We use these materials in conjunction with imaging tools (including PET and optical devices) to individualize patient care. In addition, my team explores the biological and chemical interactions of these materials at multiple spatial scales — from the cellular/molecular level to that of organs and tissues. We then link these findings to sites of disease using whole-body imaging studies of small animal models and humans. 

View Lab Overview

Research Projects

Michelle Bradbury Lab Group

Featured News

In the Lab
Stained pathology slides of a patient’s tumor (right) and of an organoid made from that tumor (left).
Five Fascinating Approaches to Cancer Science

From tropical plants and 3-D snapshots of worms to tiny particles that light up tumors, here’s a glimpse at some of the fascinating work MSK researchers pursued in 2014 as part of our quest to advance cancer science.
Novel Cancer-Targeting Investigational Nanoparticle Receives FDA IND Approval for First-In-Human Trial

Researchers at Memorial Sloan Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
Michelle Bradbury
Toward the Next Generation of Medical Imaging

Memorial Sloan Kettering researchers will explore "C dots" for tumor detection and treatment.

Publications

Thulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro A, Yamada J, Bradbury MS.  Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. Clinical Cancer. Research Published Online January 4th , 2019. Doi: 10.1158/1078-0432.CCR-18-2079. 

Chen F, Ma K, Madajewski B, Zhuang L, Zhang L, Rickert K, Marelli M, Yoo B, Turker MZ, Overholtzer M, Quinn TP, Gonen M, Zanzonico P, Tuesca A, Bowen MA, Norton L, Subramony JA, Wiesner U, Bradbury MS. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat Commun. 9(1):4141, 1-11, 2018.

Chen F, Zhang X, Ma K, Madajewski B, Benezra M, Zhang L, Phillips E, Turker MZ, Gallazzi F, Penate-Medina O, Overholtzer M, Pauliah M, Gonen M, Zanzonico P, Wiesner U, Bradbury MS, Quinn TP.  Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging.  ACS Appl Mater Interfaces.10 (5):4379-4393, 2018.  

Hartshorn CM, Bradbury MS, Lanza GM, Nel AE, Rao J, Wang AZ, Wiesner UB, Yang L, Grodzinski P. Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS Nano. 12(1):24-43, 2018.

Chen F, Ma K, Benezra M, Zhang L, Cheal SM, Phillips E, Yoo B, Pauliah M, Overholtzer M, Zanzonico P, Sequeira S, Gonen M, Quinn T, Wiesner U, Bradbury MS.  Cancer-Targeting Ultrasmall Silica Nanoparticles for Clinical Translation: Physicochemical Structure and Biological Property Correlations.  Chem Mater. 29(20):8766-8779, 2017.

View All Publications

People

Dr. Michelle Bradbury

Michelle S. Bradbury, MD, PhD

Director of Intraoperative Imaging, Radiology

  • Clinician-scientist Michelle Bradbury develops translational, tumor-targeting, PET-optical silica nanoparticle probes for diagnostics, drug delivery, and sensing.
  • PhD – Massachusetts Institute of Technology, Cambridge, MA
  • MD – George Washington University, School of Medicine, Washington, DC
bradburm@mskcc.org
Email Address
646-888-3373
Office Phone
View physician profile
Physician profile

Members

Luis Campodonico, MA
Luis Campodonico

Departmental Fund Manager (DFM)

Feng Chen, PhD
Feng Chen

Senior Research Scientist

Nick P.M. Chen, PhD
Nick P.M. Chen

Visiting Investigator

Pocharapong (Pete) Jenjitranant, MD
Pocharapong (Pete) Jenjitranant

Visiting Investigator

Rupa Juthani, MD
Rupa Juthani

Visiting Investigator

Brian Madajewski

Research Fellow

Virginia Aragon Sanabria
Virginia Aragon Sanabria
Barney Yoo

Visiting Investigator

Daniella Karassawa Zanoni, MD
Daniella Karassawa Zanoni

Visiting Investigator

Li (Kenneth) Zhang, MD
Li (Kenneth) Zhang

Research Assistant

Lab Alumni
Paul Mohan

Research Associate, MRI Physicist

Evan Phillips

Research Technician

Teeraporn Suteewong

Research Fellow, Nanotechnology

Travis Williams, PhD
Travis Williams

Research Scholar

Lab Affiliations

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michelle S. Bradbury discloses the following relationships and financial interests:

  • Elucida Oncology
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: